Longitudinal Lung Function Assessment of Patients Hospitalized With COVID-19 Using 1 H and 129 Xe Lung MRI.

Autor:	Saunders LC; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Collier GJ; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Chan HF; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Hughes PJC; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Smith LJ; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Watson JGR; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Meiring JE; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Gabriel Z; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Newman T; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Plowright M; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Wade P; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Eaden JA; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Thomas S; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Strickland S; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Gustafsson L; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Bray J BSc; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Marshall H; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Capener DA; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Armstrong L; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Rodgers J; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Brook M; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Biancardi AM; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Rao MR; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Norquay G; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Rodgers O; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Munro R; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Ball JE; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Stewart NJ; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Lawrie A; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Jenkins RG; National Heart and Lung Institute, Imperial College London, London, England., Grist JT; Department of Radiology, Oxford University Hospitals, Oxford, England; Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, England; Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, England., Gleeson F; Department of Oncology, University of Oxford, Oxford, England; Department of Radiology, Oxford University Hospitals, Oxford, England., Schulte RF; GE Healthcare, Munich, Germany., Johnson KM; Department of Medical Physics, University of Madison, Madison, WI, USA., Wilson FJ; GSK, Stevenage, England., Cahn A; GSK, Stevenage, England., Swift AJ; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Rajaram S; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Mills GH; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Watson L; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Collini PJ; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England., Lawson R; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Thompson AAR; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England., Wild JM; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England. Electronic address: j.m.wild@sheffield.ac.uk.
Jazyk:	angličtina
Zdroj:	Chest [Chest] 2023 Sep; Vol. 164 (3), pp. 700-716. Date of Electronic Publication: 2023 Mar 24.
DOI:	10.1016/j.chest.2023.03.024
Abstrakt:	Background: Microvascular abnormalities and impaired gas transfer have been observed in patients with COVID-19. The progression of pulmonary changes in these patients remains unclear. Research Question: Do patients hospitalized with COVID-19 without evidence of architectural distortion on structural imaging exhibit longitudinal improvements in lung function measured by using 1 H and 129 Xe MRI between 6 and 52 weeks following hospitalization? Study Design and Methods: Patients who were hospitalized with COVID-19 pneumonia underwent a pulmonary 1 H and 129 Xe MRI protocol at 6, 12, 25, and 51 weeks following hospital admission in a prospective cohort study between November 2020 and February 2022. The imaging protocol was as follows: 1 H ultra-short echo time, contrast-enhanced lung perfusion, 129 Xe ventilation, 129 Xe diffusion-weighted, and 129 Xe spectroscopic imaging of gas exchange. Results: Nine patients were recruited (age 57 ± 14 [median ± interquartile range] years; six of nine patients were male). Patients underwent MRI at 6 (n = 9), 12 (n = 9), 25 (n = 6), and 51 (n = 8) weeks following hospital admission. Patients with signs of interstitial lung damage were excluded. At 6 weeks, patients exhibited impaired 129 Xe gas transfer (RBC to membrane fraction), but lung microstructure was not increased (apparent diffusion coefficient and mean acinar airway dimensions). Minor ventilation abnormalities present in four patients were largely resolved in the 6- to 25-week period. At 12 weeks, all patients with lung perfusion data (n = 6) showed an increase in both pulmonary blood volume and flow compared with 6 weeks, although this was not statistically significant. At 12 weeks, significant improvements in 129 Xe gas transfer were observed compared with 6-week examinations; however, 129 Xe gas transfer remained abnormally low at weeks 12, 25, and 51. Interpretation: 129 Xe gas transfer was impaired up to 1 year following hospitalization in patients who were hospitalized with COVID-19 pneumonia, without evidence of architectural distortion on structural imaging, whereas lung ventilation was normal at 52 weeks. (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu